Skip to content

The pRCT study of the FTZ therapeutic characteristics on senile type-two diabetes

The pRCT study of the FTZ therapeutic characteristics on senile type-two diabetes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOQ-17012072
Enrollment
Unknown
Registered
2017-07-20
Start date
2017-07-01
Completion date
Unknown
Last updated
2017-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus type 2

Interventions

????:??????
routine treatment group+FTZ:compound Zhenzhu Tiaozhi capsule

Sponsors

Guangdong Pharmaceutical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. previous diagnosis of type 2 diabetes age = 60 years of age with independent function and only having oral hypoglycemics agents; 2. volunteer to participate in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Serious hypertension (SBP = 200 mmHg), severe cardiopulmonary insufficiency, serious arrhythmia and hematopoietic system and other serious primary disease, tumors, liver and kidney dysfunction and mental illness; 2. Diabetic ketoacidosis and infection in nearly one month; 3. Hypersensitive or allergies to a variety of drugs; 4. Patients who participated in other drug clinical studies or were participating in other clinical studies within one month prior to participating in the study or combined with other Traditional Chinese Medicines.

Design outcomes

Primary

MeasureTime frame
HbA1C;glucose;

Countries

China

Contacts

Public ContactShenghua Piao

Guangdong Pharmaceutical University

790702273@qq.com+86 13434217528

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026